Strict ORS Labeling Rules Drive Major India Sales Dip

The Indian pharmaceutical market recently witnessed a significant shift following the strict enforcement of WHO ORS Labelling Norms. According to recent data, sales for oral rehydration solutions (ORS) dropped by 26% in March. This decline directly follows the government's crackdown on sugary and fruit-based beverages that previously used the ORS label. Consequently, pharmaceutical companies are adjusting to a market where only medically compliant formulations can use the therapeutic designation. Experts suggest that the removal of misleading products is the primary driver behind this unusual seasonal sales pattern.

Understanding WHO ORS Labelling Norms

The Food Safety and Standards Authority of India (FSSAI) recently implemented a landmark ban to protect vulnerable patients. Specifically, manufacturers can no longer label sugary drinks as ORS unless they meet WHO ORS Labelling Norms. Previously, many beverages masqueraded as medical rehydration salts despite containing excessive sugar levels. These sugary substitutes often contained ten times the glucose amount recommended for therapeutic use. Therefore, clinicians noticed that these products frequently worsened diarrhea in pediatric patients rather than treating it effectively. Moreover, the new regulations mandate that therapeutic ORS must fall under the purview of the CDSCO instead of the FSSAI.

Impact on the Pharmaceutical Landscape

PharmaTrac reports indicate that the sector's value growth declined significantly this year due to these regulatory changes. For example, February and March sales stood at ₹80 crore and ₹85 crore, down from over ₹110 crore in previous years. Even market leaders like Electral saw a 7% decline in moving annual total sales. Additionally, the FSSAI's intervention dismantled long-standing marketing architectures built around these non-compliant brands. However, medical experts argue this correction is essential for long-term public health. Dr. Sivaranjani Santosh highlighted that misbranded products previously led to numerous child hospitalizations across India. Consequently, the medical community is now steering parents away from commercial formulations altogether.

Frequently Asked Questions

Q1: Why are ORS sales in India declining despite the summer season?

Sales are declining because new FSSAI regulations prevent sugary and fruit-based drinks from using the 'ORS' label. This has led to the withdrawal of many misbranded products that previously inflated market figures.

Q2: Who regulates therapeutic ORS products under the new Indian norms?

Manufacturers of genuine therapeutic ORS must now seek permission from the Central Drugs Standard Control Organisation (CDSCO). This ensures that products labeled as ORS meet strict medical standards rather than just general food safety rules.

Q3: Why were sugary drinks marketed as ORS considered a health concern?

Many commercial drinks contained 110-120g of sugar per liter, which is nearly ten times the amount permitted by WHO standards. This high sugar content can cause osmotic diarrhea, worsening dehydration in children instead of treating it.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. ORS sales melt in March after govt's stricter labelling norms - ETHealthworld


2. Food Safety and Standards Authority of India (FSSAI). Directive on Misleading ORS Labelling, October 2025.


3. World Health Organization. WHO/UNICEF Technical Manual: Oral Rehydration Salts (ORS) Formulation and Use.